Suscribirse

Hypoglycemia-associated Mortality Is Not Drug-associated but Linked to Comorbidities - 20/10/11

Doi : 10.1016/j.amjmed.2011.07.011 
Laura Boucai, MD, MS a, b, , William N. Southern, MD, MS a, c, Joel Zonszein, MD, CDE, FACP, FACE a, b
a Department of Medicine, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, NY 
b Division of Endocrinology, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, NY 
c General Internal Medicine, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, NY 

Requests for reprints should be addressed to Laura Boucai, MD, MS, Montefiore Medical Center, Department of Medicine, Division of Endocrinology and Metabolism, 1300 Morris Park Avenue, Belfer Building 701, Bronx, NY 10461

Abstract

Objective

Although tight glucose control is used widely in hospitalized patients, there is concern that medication-induced hypoglycemia may worsen patient outcomes. We sought to determine if the mortality risk associated with hypoglycemia in hospitalized noncritically ill patients is linked to glucose-lowering medications (drug-associated hypoglycemia) or merely an association mediated by comorbidities (spontaneous hypoglycemia).

Methods

A retrospective cohort of patients admitted to the general wards of an academic center during 2007 was studied. The in-hospital mortality risk of a hypoglycemic group (at least 1 blood glucose70 mg/dL) was compared with that of a normoglycemic group using survival analysis. Stratification by subgroups of patients with spontaneous and drug-associated hypoglycemia was performed.

Results

Among 31,970 patients, 3349 (10.5%) had at least 1 episode of hypoglycemia. Patients with hypoglycemia were older, had more comorbidities, and received more antidiabetic agents. Hypoglycemia was associated with increased in-hospital mortality (hazard ratio [HR], 1.67; 95% confidence interval [CI], 1.33-2.09; P<.001). However, this greater risk was limited to patients with spontaneous hypoglycemia (HR, 2.62; 95% CI, 1.97-3.47; P<.001) and not to patients with drug-associated hypoglycemia (HR, 1.06; 95% CI, 0.74-1.52; P=.749). After adjustment for patient comorbidities, the association between spontaneous hypoglycemia and mortality was eliminated (HR, 1.11; 95% CI, 0.76-1.64; P=.582).

Conclusion

Drug-associated hypoglycemia was not associated with increased mortality risk in patients admitted to the general wards. The association between spontaneous hypoglycemia and mortality was eliminated after adjustment for comorbidities, suggesting that hypoglycemia may be a marker of disease burden rather than a direct cause of death.

El texto completo de este artículo está disponible en PDF.

Keywords : Hypoglycemia, Hypoglycemia in general ward patients, Mortality


Esquema


 Funding: This publication was made possible by the Clinical and Translational Science Award Grant UL1 RR025750 and KL2 RR025749 and TL1 RR025748 from the National Center for Research Resources, a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessary represent the official view of the National Center for Research Resources or NIH.
 Conflict of Interest: LB, WNS, and JZ have not received any support from any organization for the submitted work. LB and WNS have no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years. JZ serves on an advisory panel for Takeda Pharmaceutical North America and on the speakers bureau for Amylin Pharmaceuticals, Eli Lilly, Merck, Novo Nordisk, and Sanofi-Aventis.
 Authorship: LB, WNS, and JZ had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. LB designed the study, researched the data, wrote, reviewed, and edited the manuscript. WNS contributed to data collection, researched the data, and contributed to writing, reviewing, and editing the manuscript. JZ contributed to designing the study, writing, reviewing, and editing the manuscript.


© 2011  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 124 - N° 11

P. 1028-1035 - novembre 2011 Regresar al número
Artículo precedente Artículo precedente
  • Double Trouble
  • Laszlo Littmann, Michael W. Haley
| Artículo siguiente Artículo siguiente
  • Naproxen as Prophylaxis against Atrial Fibrillation after Cardiac Surgery: The NAFARM Randomized Trial
  • Stevie J. Horbach, Renato D. Lopes, João C.V. da C. Guaragna, Felipe Martini, Rajendra H. Mehta, João B. Petracco, Luis C. Bodanese, Adauto C. Filho, Cláudio Cirenza, Angelo A.V. de Paola, NAFARM Investigators ⁎

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.